ALK and non-small cell lung carcinoma: Patients with advanced NSCLC harboring ALK rearrangements are routinely treated with ALK tyrosine kinase inhibitors (TKIs), including the first generation crizotinib, the second generation ALK TKIs alectinib, brigatinib and ceritinib, and the third generation lorlatinib [4].